Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Prednisolone; Prednisolone; Prednisone; Prednisone
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBERTY ASTHMA VOYAGE; VOYAGE
  • Sponsors Sanofi

Most Recent Events

  • 23 Dec 2025 According to Regeneron pharmaceuticals media release, based on data from this study the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma.
  • 01 May 2025 According to Regeneron pharmaceuticals media release, data from this study will be presented at the American Thoracic Society (ATS) International Conference 2025 being held from May 18 to 21 in San Francisco, California.
  • 26 Apr 2024 According to a Sanofi media release, post-hoc data from this study will be presented at the American Thoracic Society (ATS) International Conference taking place from May 17-22 in San Diego.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top